Novavax doubles its potential COVID-19 vaccine manufacturing capacity to 2 Billion Doses

HLN00CPO-COVID-vaccine-vial2.jpg


U.S. Pharma bggie Novavax said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India.

In August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low and middle-income countries and India.

As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX-CoV2373, which Novavax said will bring its manufacturing capacity to over two billion doses by mid-2021.

Novavax's vaccine is currently in mid-stage trials after an early-stage study showed it produced high levels of antibodies against the novel coronavirus. The company plans to begin late-stage trials in the third quarter.

The company is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine, and has also signed supply agreements with Canada and Japan.
About author
Davidisms
David is an avid Technology enthusiast. Football is Love. Cinema Connoisseur.

Comments

There are no comments to display.

Article information

Author
Davidisms
Views
47
Last update

More in Health & Fitness

More from Davidisms

Top